ESMO 2026: Breast Cancer Pro Portal

View Session

ESMO 2026: ctDNA Detection Rates During Surveillance In High-Risk HR+/HER2 Negative Breast Cancer From the TRAK-ER Study

Lajos Pusztai, MD, DPhil
Hope Rugo, MD

8:40 Minutes

View Session

ESMO 2026: Key Take Aways - Translational Research

Masakazu Toi, MD, PhD

4:20 Minutes

View Session

ESMO 2026: Capivasertib (C) and Fulvestrant (F) for Patients with HR+/HER2 Advanced Breast Cancer (ABC): Final Overall Survival (OS) Results from the Phase 3 CAPItello-291 Trial

Hope Rugo, MD

5:15 Minutes

View Session

ESMO 2026: Risk Reducing Surgery and Survival in BRCA Mutation Carriers

Matteo Lambertini, MD, PhD

5:15 Minutes

View Session

ESMO 2026: First-line (1L) Datopotamb Deructecan (Dato-DXd) vs Chemotherapy (CT) in Patients with Locally Recurrent Inoperable or (mTNBC) for Whom Immunotherapy was Not an Option: Patient-Reported Outcomes (PROs) from TROPION-Breast02

Janice Tsang, MD

5:15 Minutes

View Session

ESMO 2026: Safety and (PROs) from evERA Breast Cancer: A phase III trial of (GIRE) + everolimus (E) in pts with oestrogen receptor-positive, HER2-negative advanced breast cancer(ER+, HER2,-aBC) previously treated with a CDK4/6 inhibitor (i)

Janice Tsang, MD

5:15 Minutes

View Session

ESMO 2026: From Clinical Criteria to Actionable Biomarkers. Guiding Neoadjuvant and Adjuvant.

Nadia Harbeck, MD, PhD

4:00 Minutes

View Session

ESMO 2026: Evolving Standards in 2L ER+ HER2+ MBC

Nadia Harbeck, MD, PhD

4:00 Minutes

View Session

ESMO 2026: 5-year Invasive Disease-Free Survival (iDFS) of the Strategy Based, Randomized Phase II PHERGain Trial Evaluating Chemotherapy (CT) De-Escalation in HER2(+) Early Breast Cancer (EBC) Patients (pts)

Matteo Lambertini, MD, PhD

3:00 Minutes

View Session

ESMO 2026: ADCs in Metastatic HR+ HER2 BC: Clinical Evidence and Future Directions

Virginia Kaklamani, MD, DSc

4:00 Minutes

View Session

ESMO 2026: Lifestyle and Breast Cancer: What the Evidence Tells Us

Neil Iyengar, MD
Hope Rugo, MD

10:00 Minutes

View Session

ESMO 2026: Residual Cancer Burden (RCB) Following Neoadjuvant Treatment (NAT) with T-DXd→THP vs Dose-Dense Doxorubicin + Cyclophosphamide→THP (ddAC-THP) in High-Risk HER2+ Early-Stage Breast Cancer (eBC)

Lajos Pusztai, MD, DPhil

2:40 Minutes

View Session

ESMO 2026: A window-of-opportunity (WOO) trial of giredestrant +/- LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+/HER2- early breast cancer: PREcoopERA

Elisabetta Munzone, MD
Hope Rugo, MD

6:00 Minutes

2026 ESMO Video Highlights

Supported by Educational Grants From Stemline/Menarini and Gilead

All Videos Now Available!